Puma Biotechnology (NYSE: PBYI) is trading more than 180 percent higher after-hours as news hit that the company released positive top line results from its Phase 3 PB272 trial in initial treatment for breast cancer.
The trial showed that with treatment, clients showed a 33 percent improvement in disease free survival versus placebo. According to the company website PB272 is:
"...a potent irreversible tyrosine kinase inhibitor, or TKI, that blocks signal transduction through the epidermal growth factor receptors, or EGFRs, HER1, HER2 and HER4. We believe neratinib has clinical application in the treatment of several cancers, including breast cancer and gastric cancer. Our initial focus is on the development of neratinib as an oral treatment for patients with HER2-positive breast cancer."
A list of the 32 studies found for Puma Biotechnology at ClinicalTrials.gov
See more from Benzinga
- Mid-Afternoon Market Update; ISM Revised Twice, CONN Maintains Gains On Earnings Report
- Mid-Day Market Update: MasTec Tumbles On Weak Forecast; Protective Life Shares Spike Higher
- Mid-Morning Market Update: Markets Fall; Conn's Profit Beats Street View
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- Health Care Industry
- breast cancer